LAWRENCEVILLE, N.J., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- IMUNON, Inc. ( NASDAQ: IMNN ) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C.

LAWRENCEVILLE, N.J., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- IMUNON, Inc. ( Nasdaq: IMNN ) , a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders ...

Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate, IMNN-001. The market's back, and these 3 income stocks are thriving. See them here→

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

LAWRENCEVILLE, N.J., July 29, 2025 ( GLOBE NEWSWIRE ) -- IMUNON, Inc. ( NASDAQ: IMNN ) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m.

Stock Dividend Reflects Company's Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders ...

Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance ...

ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ...

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress ...